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Abstract

A 68-year-old morbidly obese female
with a history of hypertension, diabetes
mellitus, hyperlipidemia, obstructive sleep
apnea, osteoarthritis, depression/anxiety,
and about 1-month post-left total knee
replacement presented to the emergency
department with complaints of shortness of
breath, cough, wheezing, and bilateral
lower extremity pain and swelling. Her
blood pressure was 158/75 mm Hg, pulse
118 beats/minute, respiratory rate 20
breaths/minute, and temperature 37.6°C
(99.7°F). She weighed 135 kg with a body
mass index of 60 kg/m2. Laboratory studies
showed normal white blood cell count,
hemoglobin of 9.7 g/dL (normal range 11.515.5 g/dl), hematocrit of 31.1% (normal
range 34%-46%), platelets of 277x103/mm3
(normal range 140-425x103/mm3), normal
protime/international normalized ratio,
blood urea nitrogen of 23 mg/dL (normal
range 7-17 mg/dL), and normal creatinine.
Computed tomography (CT) was negative
for pulmonary embolism. Arterial duplex of
the bilateral lower leg revealed thrombus in
the left common femoral vein, likely provoked by her recent knee replacement surgery. Clinical and radiological evidence
were otherwise consistent with heart failure,
prompting admission for diuresis and medical management.
Upon admission, the patient was administered enoxaparin, 1 mg/kg subcutaneously
twice daily, for bridging to warfarin. On day
2 of admission, she had transitioned from
enoxaparin and warfarin to apixaban, 10 mg
orally twice daily. The first dose of apixaban was administered at the time that the
next usual dose of enoxaparin was due.
On day 3 of admission after 3 doses of
apixaban, the patient started complaining of
acute onset, severe abdominal pain in the
midepigastric area with radiation to the
back. At that time, she was hemodynamically stable. Her abdomen was noted to have
severe tenderness on the left to superficial
touch but otherwise was soft and non-distended. She underwent urgent CT of the
abdomen with contrast, which showed left
rectus sheath hematoma measuring approx-
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Apixaban is an oral anticoagulant that
directly inhibits Factor Xa and is indicated
for the prophylaxis and treatment of deep
venous thrombosis and stroke prevention in
non-valvular atrial fibrillation. Rectus
sheath hematoma is a rare, life-threatening
complication of anticoagulant treatment.
We describe a case of an elderly patient on
apixaban for the treatment of deep venous
thrombosis who developed severe abdominal pain during hospitalization. Computed
tomography of the abdomen revealed left
rectus sheath hematoma. Apixaban was discontinued and the patient was monitored for
extension of the hematoma. After 2 days she
was discharged home. Outpatient computed
tomography 1 month later showed complete
resolution of the rectus sheath hematoma.
We recommend that clinicians become
aware of the potential for rare and serious
bleeding complications of anticoagulants
and identify the need for early recognition
and prompt management.

Case Report

Introduction

Anticoagulants are the leading cause of
adverse drug reactions and the number one
category of medications with adverse reactions leading to hospitalization.1 The advent
of direct-acting oral anticoagulants
(DOACs) has changed the landscape of
anticoagulation treatment. Clinical trials
have shown that DOACs have at least noninferior efficacy and superior safety when
compared to vitamin K antagonists. One
potential but rare bleeding complication of
anticoagulation is rectus sheath hematoma,
which carries a risk of complications if not
diagnosed and managed appropriately.
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Rectus sheath hematoma has been reported
as a complication of traditional oral anticoagulants
and
low-molecular-weight
heparin,2,3 although thus far it has rarely
been identified in patients receiving DOAC
therapy.4
We report a case of apixaban-associated
rectus sheath hematoma in a patient initiated on anticoagulation for acute treatment of
deep vein thrombosis.
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imately 10x4x17 cm (Figure 1). Apixaban
was discontinued and she remained hemodynamically stable. An inferior vena cava
filter was placed by vascular surgery on day
4 of hospitalization, as the patient’s anticoagulation therapy was withheld in the setting of significant hematoma and acute deep
vein thrombosis. By day 5, the hemoglobin
had decreased 7.0 g/dL and the hematocrit
to 22.3%, prompting transfusion of 2 units
of packed red blood cells. No fresh frozen
plasma or prothrombin complex concentrate was administered. Two days later,
ultrasonography showed stabilization of the
hematoma, and the patient was discharged.
At her follow-up visit 1 week later, the
patient had a routine examination without
associated complaints. No pertinent findings of the leg or filter were documented on
physical examination. Her blood counts
remained stable. Outpatient CT 1 month
later showed resolution of the rectus sheath
hematoma. Aspirin, 81 mg daily, was started upon hematoma resolution in lieu of full
anticoagulation.
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Figure 1. Computed tomography image
showing left rectus sheath hematoma
measuring approximately 10x4x17 cm.
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nal pain after 1 week of dry vigorous coughing due to losartan. Losartan and rivaroxaban were discontinued and packed red
blood cells were given. No surgical intervention was required, and the patient clinically improved over time.

Conclusions
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Clinicians should have a high suspicion
of rectus sheath hematoma in patients on
anticoagulant therapy, including DOACs,
who present with acute abdominal pain and
other associated symptoms. This report
emphasizes the need for careful use of
DOACs, calling attention to the need for
appropriate monitoring assays and DOAC
reversal agents.
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Apixaban is a direct factor Xa inhibitor,
which interrupts the common pathway of
the coagulation cascade. Apixaban is
approved for the prevention and treatment
of deep vein thrombosis and pulmonary
embolism, as well as for reducing the risk of
thromboembolic stroke in patients with
non-valvular atrial fibrillation. Treatment
with apixaban does not require routine
monitoring.5 Unlike warfarin, there are no
specific antidotes for the anticoagulant
effect of the anti-Xa DOACs. As such, the
current mainstay of management of bleeding complications includes supportive care
with local measures and hemodynamic or
transfusion support. For severe bleeding,
prothrombin complex concentrate and
recombinant activated factor VII have been
recommended.6
Rectus sheath hematoma is a rare but
substantial complication associated with
significant morbidity and occasional mortality. It is the result of bleeding into the rectus sheath from damage to the superior or
inferior epigastric arteries or their branches,
or from a direct tear of the rectus muscle.7
Common risk factors and causes of rectus
sheath hematoma, while difficult to fully
evaluate given the rare incidence, include
anticoagulation, blunt or penetrating trauma
or surgical trauma, pregnancy, female gender, older age, hypertension, medical conditions such as collagen vascular disorders,
degenerative muscle diseases, or hematologic disorders and rectus muscle strain due
to exercise, and increased abdominal pressure from straining or severe coughing.7-10
Early recognition and assessment, in conjunction with timely treatment, is the cornerstone approach to reducing potential
complications associated with rectus sheath
hematoma, such as hemodynamic instability, abdominal compartment syndrome, and
occasionally death. Management of rectus

sheath hematoma depends on factors such
as the severity and size of the hematoma,
the hemodynamic status of the patient, and
the extent of anticoagulation.11 Less severe
rectus sheath hematoma is usually self-limiting and can be managed with conservative
treatment such as rest, analgesia, ice, and
compression. For patients who are hemodynamically unstable, fluid resuscitation or
blood transfusion and reversal of anticoagulation may be warranted. Higher severity
hematomas may require more invasive
management, such as angiography with
embolization or surgical exploration and
evacuation.2,3,7,8
A search of the literature identified only
3 case reports of DOAC-associated rectus
sheath hematoma, one associated with apixaban and two with rivaroxaban. Aktas et al.4
reported a spontaneous rectus sheath
hematoma in a 71-year-old female treated
with apixaban for non-valvular atrial fibrillation for 3 months prior to presentation.
The apixaban dose was appropriate per
labeled indication, although the patient had
renal impairment and was on concurrent
therapy with diltiazem, an inhibitor of Pglycoprotein and CYP3A4, posing a drug
interaction and possible increased risk of
bleeding. The rectus sheath hematoma was
diagnosed after the patient presented with
abdominal pain for 24 h, in the presence of
coughing precipitated by an upper respiratory tract infection. The patient had experienced no trauma or other inciting events.
Management was conservative, consisting
of removal of the offending agent, fluid
resuscitation, and serial hemoglobin measurements. Ultimately, the patient’s apixaban
was reinitiated at a lower dose 5 days postintervention with no further complaints at
1-week follow-up after discharge.4
Kocayigit et al.12 reported a spontaneous rectus sheath hematoma in a 75-yearold female treated with rivaroxaban for
non-valvular atrial fibrillation, initiated 3
days prior to presentation. The patient had
presented to the emergency department
with complaints of fatigue and abdominal
pain after rigorous coughing. She had no
recent trauma or surgery and was not taking
any other medications that could have contributed to the rectus sheath hematoma.
Rivaroxaban was discontinued, fluid resuscitation and packed red blood cells were
administered, and the patient was referred
to surgery due to hemodynamic instability.
The authors did not report the patient outcome.12
Talari et al.13 reported a spontaneous
rectus sheath hematoma in a 65-year-old
male treated with rivaroxaban for deep vein
thrombosis and pulmonary embolism. The
patient presented with right-sided abdomi-
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